YCT-529: a promising oral non-hormonal male contraceptive and its implications for family planning
Open Access
- 18 February 2026
- journal article
- letter
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (3) , 2460-2461
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- From concept to the clinic: Retinoic acid receptor α antagonist YCT‐529, an oral non‐hormonal male contraceptiveAndrology, 2025
- Safety and pharmacokinetics of the non-hormonal male contraceptive YCT-529Communications Medicine, 2025
- Targeting the retinoid signaling pathway with YCT-529 for effective and reversible oral contraception in mice and primatesCommunications Medicine, 2025
- Development of the retinoic acid receptor alpha-specific antagonist YCT-529 for male contraception: A brief reviewContraception, 2025